These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7850057)

  • 1. A prospective evaluation of CA15-3 in stage I carcinoma of the breast.
    O'Hanlon DM; Kerin MJ; Kent PJ; Skehill R; Maher D; Grimes H; Given HF
    J Am Coll Surg; 1995 Feb; 180(2):210-2. PubMed ID: 7850057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
    Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
    Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CA15-3: a reliable indicator of metastatic bone disease in breast cancer patients.
    O'Brien DP; Horgan PG; Gough DB; Skehill R; Grimes H; Given HF
    Ann R Coll Surg Engl; 1992 Jan; 74(1):9-11; discussion 12. PubMed ID: 1736805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
    Bensouda Y; André F; Boulet T; Al-Ghuzlan A; Conforti R; Troalen F; Bourgier C; Errihani H; Spielmann M; Delaloge S
    Bull Cancer; 2009 Oct; 96(10):923-8. PubMed ID: 19696005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Periodic measurement of serum carcinoembryonic antigen and carbohydrate antigen 15-3 levels as postoperative surveillance after breast cancer surgery.
    Nakamura T; Kimura T; Umehara Y; Suzuki K; Okamoto K; Okumura T; Morizumi S; Kawabata T
    Surg Today; 2005; 35(1):19-21. PubMed ID: 15622458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
    Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
    Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients.
    Gion M; Peloso L; Mione R; Vignati G; Fortunato A; Saracchini S; Biasioli R; Gulisano M; Cappelli G
    Cancer J; 2001; 7(3):181-90. PubMed ID: 11419026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
    Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
    Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer.
    Fehm T; Jäger W; Krämer S; Sohn C; Solomayer E; Wallwiener D; Gebauer G
    Anticancer Res; 2004; 24(3b):1987-92. PubMed ID: 15274389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CA15-3 serum levels in breast cancer and other malignancies--correlation with clinical course.
    Barak V; Carlin D; Sulkes A; Treves A; Biran S
    Isr J Med Sci; 1988; 24(9-10):623-7. PubMed ID: 3204010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of CA15.3 as a serum tumour marker in breast carcinoma.
    Duncan JL; Price A; Rogers K
    Eur J Surg Oncol; 1991 Feb; 17(1):16-9. PubMed ID: 1995353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
    Guadagni F; Ferroni P; Carlini S; Mariotti S; Spila A; Aloe S; D'Alessandro R; Carone MD; Cicchetti A; Ricciotti A; Venturo I; Perri P; Di Filippo F; Cognetti F; Botti C; Roselli M
    Clin Cancer Res; 2001 Aug; 7(8):2357-62. PubMed ID: 11489813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic significance of LIAISON(R) CA15-3 assay in primary breast cancer.
    Nisman B; Maimon O; Allweis T; Kadouri L; Maly B; Hamburger T; Peretz T
    Anticancer Res; 2013 Jan; 33(1):293-9. PubMed ID: 23267160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic role of CA15.3 in 7942 patients with operable breast cancer.
    Sandri MT; Salvatici M; Botteri E; Passerini R; Zorzino L; Rotmensz N; Luini A; Mauro C; Bagnardi V; Cassatella MC; Bottari F; Casadio C; Colleoni M
    Breast Cancer Res Treat; 2012 Feb; 132(1):317-26. PubMed ID: 22065291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma.
    Shering SG; Sherry F; McDermott EW; O'Higgins NJ; Duffy MJ
    Cancer; 1998 Dec; 83(12):2521-7. PubMed ID: 9874458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of pre-operative serum CA 15.3 levels in breast cancer.
    Martín A; Corte MD; Alvarez AM; Rodriguez JC; Andicoechea A; Bongera M; Junquera S; Pidal D; Allende T; Muñiz JL; Vizoso F
    Anticancer Res; 2006; 26(5B):3965-71. PubMed ID: 17094428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential use of tumour marker CA 15-3 in the staging and prognosis of patients with breast cancer.
    Horobin JM; Browning MC; McFarlane NP; Smith G; Preece PE; Wood RA; Cuschieri A
    J R Coll Surg Edinb; 1991 Aug; 36(4):219-21. PubMed ID: 1941734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical usefulness of tumor markers in breast cancer].
    Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F
    Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone.
    Incorvaia L; Badalamenti G; Rini G; Arcara C; Fricano S; Sferrazza C; Di Trapani D; Gebbia N; Leto G
    Anticancer Res; 2007; 27(3B):1519-25. PubMed ID: 17595770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the IMMULITE BR-MA and CEA assays and comparison with immunoradiometric assays for CA15-3 and CEA in breast cancer.
    Murray A; Willsher P; Price MR; Dixon AR; Robertson JF
    Anticancer Res; 1997; 17(3C):1945-9. PubMed ID: 9216649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.